Developing new proteins to enhance immune responses for cancer and autoimmune diseases
TR&D Project 3
This study is exploring new proteins that can help your immune system either fight off cancer and infections or calm it down for autoimmune disorders, aiming to make treatments more effective and targeted for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11134628 on NIH RePORTER |
What this research studies
This research focuses on creating innovative immunomodulatory proteins that can either boost the immune system to fight cancer and infections or suppress it to treat autoimmune disorders. By engineering natural cytokines and fusing them with antibodies, the team aims to improve the specificity, stability, and effectiveness of these proteins as therapeutic agents. This approach allows for targeted delivery to specific immune cells, potentially leading to better treatment outcomes for patients. The research utilizes advanced molecular engineering techniques to overcome the limitations of traditional cytokine therapies.
Who could benefit from this research
Good fit: Ideal candidates include patients with cancer or autoimmune disorders who may benefit from enhanced or regulated immune responses.
Not a fit: Patients with conditions unrelated to immune response modulation may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for cancer and autoimmune diseases.
How similar studies have performed: Other research has shown promise in using engineered cytokines for therapeutic purposes, indicating a potential for success with this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Spangler, Jamie Berta — Johns Hopkins University
- Study coordinator: Spangler, Jamie Berta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.